Congenital Abnormalities: all 781 studies

Page 8 of 8. Open to participants first (77), then studies with results posted, then the rest; newest registration first within each.

• Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
• OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic MalignanciesWithdrawnNCT00081055Phase 2
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00079222Not applicable
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
• 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00077558Phase 1
• 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
• Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
• BCX-1777 in Treating Patients With Refractory CancerCompletedNCT00073944Phase 1
• GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00070551Phase 1
• VNP40101M and Cytarabine in Treating Patients With Hematologic MalignanciesCompletedNCT00070538Phase 1
• Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CMLTerminatedNCT00069992Phase 2
• Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
• S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00066794Phase 2
• Peripheral Stem Cell Transplant in Treating Patients With High-Risk LeukemiaTerminatedNCT00066417Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic CancerCompletedNCT00064285Phase 1
• 3-AP and Cytarabine in Treating Patients With Hematologic CancerCompletedNCT00064090Phase 1
• Esophageal Motility and Airway Defenses Among InfantsCompletedNCT00062452
• Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With CancerTerminatedNCT00062231Not applicable
• Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00062140Phase 1
• Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00060255Phase 2
• Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderCompletedNCT00054340Phase 1/2
• Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
• Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDSCompletedNCT00053287Phase 2
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic CancerCompletedNCT00053196Phase 2
• Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaCompletedNCT00053157Not applicable
• Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
• Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
• Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00052299Phase 3
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00049179Phase 2
• Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or LymphomaCompletedNCT00047021Phase 2
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00044954Phase 2
• FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00042822Phase 2
• Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00039117Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced CancerCompletedNCT00036790Phase 1
• Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
• Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous LeukemiaCompletedNCT00017342Phase 2
• MS-275 in Treating Patients With Hematologic CancerCompletedNCT00015925Phase 1
• Pesticides--Health Fertility and Reproductive RiskCompletedNCT00015561
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic CancerCompletedNCT00014469Phase 2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic DisordersStatus unknownNCT00008307Phase 2
• Blood Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00008216
• Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00008177Phase 1
• Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic AnemiaStatus unknownNCT00008164Phase 2
• Non-Ablative Allo HSCT For Hematologic Malignancies or SAACompletedNCT00006379Phase 2
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• Phenylbutyrate and Tretinoin in Treating Patients With Hematologic CancerCompletedNCT00006239Phase 1
• Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00006042Phase 1
• Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First RemissionCompletedNCT00005940Phase 2
• Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00005863Phase 3
• Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00005823Phase 3
• Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic LeukemiaCompletedNCT00005802Phase 1/2
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
• Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 2
• A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and EtoposideCompletedNCT00005793Phase 1/2
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00005622Phase 2
• Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of HolopresencephalyCompletedNCT00005016
• Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004899Phase 2
• Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004896Phase 2
• Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaCompletedNCT00004245Phase 1
• Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaStatus unknownNCT00004128Phase 3
• 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow DisorderTerminatedNCT00004058Phase 1
• Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid LeukemiaCompletedNCT00003868Phase 2
• Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic CancerCompletedNCT00003335Phase 2
• Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00003190Phase 3
• High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003116Phase 2
• Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic CancerCompletedNCT00002809Phase 2
• Study of Abnormal Blood Clotting in Children With StrokeCompletedNCT00001927
• Evaluation of Patients With Unresolved Chromosome AbnormalitiesCompletedNCT00001639
• Studies of Families With Hereditary CataractsCompletedNCT00001609
• Diagnosis and Treatment of Patients With Cystic FibrosisTerminatedNCT00001223
• Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and LensCompletedNCT00001161

← Congenital Abnormalities overview